Benserazide

DRUG2 trials

Sponsors

Bial - Portela C S.A.

Conditions

Parkinson's Disease

Phase 3

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

CompletedNCT01227655

Bial - Portela C S.A.Parkinson's Disease

Start: 2011-03-31End: 2012-07-31Updated: 2015-10-19

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon

CompletedNCT01568073

Bial - Portela C S.A.Parkinson's Disease

Start: 2011-03-31End: 2013-11-30Updated: 2015-09-18

Related Papers

The Cost-Effectiveness of Opicapone Versus Entacapone as Adjuvant Therapy for Levodopa-Treated Individuals With Parkinson's Disease Experiencing End-of-Dose Motor Fluctuations.

2025-09-11

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations

JAMA Neurology2016-12-27177 citations

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

2015-12-23158 citations